Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant S1, Oxaliplatin, and Docetaxel (SLOT) Versus S1, Oxaliplatin(SOX) in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer

NCT02512380 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT02512380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02512380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant S1, Oxaliplatin, and Docetaxel (SLOT) Versus S1, Oxaliplatin(SOX) in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer
Lead sponsor
Chinese Academy of Medical Sciences
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2015
Completion date
July 31, 2021
Enrollment
380 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma